drugset / Trial / NCT00265993

Enoxaparin in Acute Venous Thromboembolic Disease

NCT00265993

Phase 4 Completed 251 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study objectives : * To evaluate the efficacy/safety profile of enoxaparin once a day treatment in acute venous thromboembolic disease.

Timeline

Start
2004-12
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Enoxaparin sodium Other / unclassified 1.5 mg/kg Subcutaneous